CIPAMI-Study: Clopidogrel administered prehospital to improve primary PCI in Patients with Acute Myocardial Infarction - CIPAMI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-000516-24-DE

Enrollment

654

Registered

2006-05-05

Start date

2006-08-28

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial infarction (STEMI) < 6 hrs. MedDRA version: 8.1 Level: LLT Classification code 10000891 Term: Acute myocardial infarction

Interventions

Trade Name: Iscover 75mg Filmtabletten Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Clopidogrel Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Acute STEMI =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Thrombolytic therapy within 24 hrs. Effective oral or intravenuous anticoagulation Hemorrhagic diathesis Stroke/TIA within 3 months Active gastrointestinal or urogenital bleeding Major surgery (including CABG) within 6 weeks Contraindication to Clopidogrel Pregnancy/Lactation period Women with childbearing potential Treatment with Clopidogrel or Ticlopidine within the last 10 days

Design outcomes

Primary

Measure	Time frame
Main Objective: Evaluation of efficacy, feasibilty, and safety of the administration of a high loading dose clopidogrel in the very early phase of STEMI in the prehospital setting;Secondary Objective: Complications as death, re-MI, urgent revascularisation, stroke, severe bleedings;Primary end point(s): TIMI 2/3 patency of the infarct-related artery immediately prior to PCI	—

Countries

Austria, Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026